Drug details

Sublocade (buprenorphine injection for subcutaneous use)

type of Analgesics, Opioid Partial Agonist

Sublocade (buprenorphine extended-release) Injection contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Sublocade should be used as part of a complete treatment program that includes counseling and psychosocial support.

This drug may have the following side effects:

• nausea,
• loss of appetite,
• itching,
• dark urine,
• rash,
• vomiting,
• diarrhea,
• weight loss,
• confusion,
• stomach pain,
• yellowing of the skin or eyes (jaundice),
• fainting,
• agitation,
• unusual tiredness,
• mood changes,
• fast or irregular heartbeat,
• severe stomach pain,
• anxiety,
• trouble sleeping,
• severe dizziness, and
• trouble breathing
• irritability,
• hallucinations,
• unusual drowsiness,
• interrupted breathing during sleep,
• muscle stiffness,
• severe dizziness,
• slow or shallow breathing,
• shakiness,
• difficulty waking up,
• swelling of the face, tongue, throat,

The following drugs are related to Sublocade, either as a replacement or used together:

• Brixadi (buprenorphine extended-release injection)
• Dilaudid (hydromorphone hydrochloride)
• Dilaudid-HP (hydromorphone hydrochloride injection)
• Vicodin ES (hydrocodone bitartrate and acetaminophen)
• Opvee (nalmefene nasal spray)